Hematinics - Therapeutic use
Research News and Information

Monday, March 22, 2010

Use of agents stimulating erythropoiesis in digestive diseases.

5 Oct 2009 Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are ... Read more...

Iron sequestration and anemia of inflammation.

29 Sep 2009 Anemia of chronic disease, also called anemia of inflammation, is characterized by hypoferremia due to iron sequestration that eventually results in iron-restricted erythropoiesis. During the last decade, the molecular mechanisms of iron ... Read more...

Mutations in the gene encoding DMT1: clinical presentation and treatment.

29 Sep 2009 Divalent metal transporter 1 (DMT1) is the protein that allows elemental iron entry into the duodenal cell. It is expressed ubiquitously and it also allows the iron exit from the endosomes. This protein plays a central role in iron metabolism and it ... Read more...

Latest indexed articles for 'Hematinics - Therapeutic use'

These are the very latest articles for this heading:

• Use of agents stimulating erythropoiesis in digestive diseases. 5 Oct 2009
• Iron sequestration and anemia of inflammation. 29 Sep 2009
• Mutations in the gene encoding DMT1: clinical presentation and treatment. 29 Sep 2009
• The new age of iron: evaluation and management of iron-restricted erythropoiesis. 29 Sep 2009
• [Pharmaceutical treatment of cancer-associated fatigue--a survey of a Cochrane review] 19 Sep 2009
• Guidelines for Epo use in children with cancer. 30 Aug 2009
• [Toxic hematologic side effects of chemotherapy: nursing interventions] 30 Jul 2009
• A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. 28 Jul 2009
• Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial). 26 Jul 2009
• Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment. 13 Jul 2009
• The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. 5 Jul 2009
• Assessing the quality of prescribing and monitoring erythropoiesis-stimulating agents in the nursing home setting. 29 Jun 2009
• Use of erythropoietin-stimulating agents in breast cancer patients: a risk review. 29 Jun 2009
• The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo). 29 Jun 2009
• 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. 29 Jun 2009
• Hepcidin for clinicians. 23 Jun 2009
• Treating anemia with erythropoiesis-stimulating agents: effects on quality of life. 20 Jun 2009
• Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). 3 Jun 2009
• Brucellosis triggering hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency. 31 May 2009
• Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia. 30 May 2009

See a longer list of these articles.

Technical information about 'Hematinics'

Definition: Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias.

Registry Number: 0

Descriptor UI: D006397

Alternative terms: Hematinics; Hematopoietic Agents; Erythropoiesis Stimulating Agents;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.502.543;

History Note: 75